Clinical trials: Platinum-Resistant Ovarian Cancer
EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer
A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors
CIBI363A203, a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of IBI363 combined with IBI305 (a bevacizumab biosimilar) in participants with advanced malignancies conducted in China.
- Trial name
- NCT07124793
- Testing
- IBI363+IBI305
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
- Trial name
- NCT06730347
- Testing
- Lorigerlimab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- MacroGenics
Ovarian Cancer
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with…
- Trial name
- NCT02580058
- Testing
- avelumab, PLD
- Where
- 295 sites in United States, Australia and 23 more
- Volunteers
- 566 people
- Sponsor
- Pfizer
High-grade Serous Ovarian Cancer (HGSOC)
Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian carcinoma. Platinum-based drugs are the first-line chemotherapeutic agents for HGSOC, but platinum resistance and prognosis are difficult to…
- Trial name
- PPRPHGSOC (NCT06787170)
- Testing
- MRI habitat imaging
- Where
- China
- Volunteers
- 1,129 people
- Sponsor
- The First People's Hospital of Yunnan
Objective Response Rate
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel） and bevacizumab to treat patients with recurrent…
- Trial name
- NCT04670978
- Testing
- albumin-bound paclitaxe combined with bevacizumab biosimilar
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shandong University
Ovarian Cancer
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in…
- Trial name
- IPROC (NCT04918186)
- Testing
- Durvalumab, BA3011, BA3021
- Where
- 6 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Cancer Trials Group
Epithelial Ovarian Cancer, Peritoneal Cancer
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
This Phase III single-arm study is to evaluate the efficacy and safety of IMGN853 in Chinese adult patients with platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers (hereafter referred…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05622890
- Testing
- Mirvetuximab Soravtansine
- Where
- 28 sites in China
- Volunteers
- 35 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer
Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
The purpose of this study is to investigate the response rate in platinum-resistant, KRAS wild-type, ovarian cancer patients who are treated with pegylated liposomal doxorubicin (Caelyx®) in combination with biological treatment…
- Trial name
- PaLiDo (NCT00861120)
- Testing
- Pegylated liposomal doxorubicin, Panitumumab
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 33 people
- Sponsor
- Vejle Hospital
Ovarian Cancer
Gene Therapy in Treating Patients With Ovarian Cancer
Phase I trial to study the effectiveness of gene therapy in treating patients with ovarian cancer that has not responded to previous treatment.
- Trial name
- NCT00003588
- Testing
- Ad5CMV-p53 gene, laparoscopic surgery
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brenner Tumor, Fallopian Tube Cancer
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
This phase II trial is studying how well giving belinostat together with carboplatin works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that did…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT00993616
- Testing
- belinostat, carboplatin
- Where
- 81 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Trial name
- TIVO (NCT01853644)
- Testing
- Tivozanib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Platinum-resistant Recurrent Ovarian Cancer
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
This study is a pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer. More specifically, this is a randomized, multi-center, open label, phase II study for Homologous…
- Trial name
- NCT03699449
- Testing
- olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment
- Where
- 3 sites in South Korea
- Volunteers
- 104 people
- Sponsor
- Yonsei University
Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum…
- Trial name
- NCT05225363
- Testing
- Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, Primary Peritoneal Cancer
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination…
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01196559
- Testing
- Vinorelbine and Gemcitabine
- Where
- 4 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- The Catholic University of Korea
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent…
- Trial name
- NCT00003523
- Testing
- aminocamptothecin colloidal dispersion
- Where
- 65 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian…
- Trial name
- NCT00102622
- Testing
- Intraperitoneal tgDCC-E1A, Paclitaxel
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Non-small Cell Lung Cancer
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian…
- Trial name
- NAPISTAR1-01 (NCT06303505)
- Testing
- TUB-040
- Where
- 29 sites in United States, Belgium and 6 more
- Volunteers
- 250 people
- Sponsor
- Gilead Sciences
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of bevacizumab and Abraxane in the treatment of women with epithelial ovarian cancer or peritoneal cancer.
- Trial name
- NCT00407563
- Testing
- Bevacizumab, Abraxane
- Where
- 11 sites in United States
- Volunteers
- 48 people
- Sponsor
- Accelerated Community Oncology Research Network
Platinum-resistant Advanced Ovarian Cancer
Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Given the low Responses Rates and short survival times achieved with conventional cytotoxic agents in resistant ovarian cancer patients, new treatment options are needed in this patient population.Antiangiogenic therapy has an…
- Trial name
- NCT01262014
- Testing
- Pazopanib
- Where
- 20 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
The study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy with pembrolizumab in recurrent, platinum resistant OC patients.
- Trial name
- MITO27 (NCT03539328)
- Testing
- Pembrolizumab, Gemcitabine, Paclitaxel
- Where
- Italy
- Volunteers
- 138 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano